In response to RFA-DA-05-001, this application requests continuation of the Pacific Region Node of the """"""""National Drug Abuse Treatment Clinical Trials Network"""""""" (CTN). The research, training, and dissemination activities of the Pacific Region Node will continue to serve the CTN objective """"""""to improve the quality of drug abuse treatment throughout the country, using science as a vehicle."""""""" The first five years of the CTN have demonstrated the Pacific Region Node's ability to significantly contribute to the overall CTN effort in terms of research productivity, innovative concept development, rigorous conduct of research, efficient management and administration, and effective dissemination of results. For example, Node participants developed and implemented the first three CTN protocols, developed training materials, procedures, and manuals adopted for use across the CTN, initiated and hosted several CTN-oriented conferences, and extensively disseminated CTN-based findings through trainings, presentations, publication, and Internet-based methods. The Node's activities will continue to advance the science and increase practical application of research-proven treatments in a collaborative manner with other nodes, with the CTN community treatment providers (CTPs), and with other providers and researchers around the country. This renewal proposes adding three more CTPs to the existing five, increasing representation to account for greater diversity in setting, modality, special population, and drug abuse problem. The Pacific Region Node intends to accelerate identification, development, and testing of new medications and behavioral therapies by increasing interaction with other research efforts involving promising therapies. In addition to participation in the CTN, the Pacific Region Node benefits from association with cutting-edge research on medications for drug abuse emerging from the Node's UCLA environment;for example, UCLA's P50-funded Medication Development Unit for Stimulant Abuse (Shoptaw), the UCLA-led Methamphetamine Clinical Trials Group (Rawson), the UCLA Clinical Trials Operations Unit (Ling, Rawson and Shoptaw, Phase I and II trials), and other investigations of promising medications and behavioral therapies for treating drug abusers (Ling, Rawson, Shoptaw, Roll, Newton, Longshore) all provide information useful in developing and testing potential CTN protocols.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA013045-10S4
Application #
8063360
Study Section
Special Emphasis Panel (ZDA1-MXG-S (02))
Program Officer
Dobbins, Ronald
Project Start
1999-09-30
Project End
2010-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
10
Fiscal Year
2010
Total Cost
$745,343
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Zhu, Yuhui; Evans, Elizabeth A; Mooney, Larissa J et al. (2018) Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol 13:488-497
Crist, R C; Doyle, G A; Nelson, E C et al. (2018) A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 18:173-179
Crist, Richard C; Li, James; Doyle, Glenn A et al. (2018) Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse 44:431-440
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531
Garrett, Sharon B; Doyle, Suzanne R; Peavy, K Michelle et al. (2018) Age differences in outcomes among patients in the ""Stimulant Abuser Groups to Engage in 12-Step"" (STAGE-12) intervention. J Subst Abuse Treat 84:21-29
Tomko, Rachel L; Baker, Nathaniel L; McClure, Erin A et al. (2018) Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend 182:1-7
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80
Hser, Yih-Ing; Huang, David; Saxon, Andrew J et al. (2017) Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine?+?Naloxone and Methadone. J Addict Med 11:63-69

Showing the most recent 10 out of 112 publications